A fresh look at the definition of susceptibility of Streptococcus pneumoniae to β-lactam antibiotics

被引:44
作者
Musher, DM
Bartlett, JG
Doern, GV
机构
[1] Vet Affairs Med Ctr, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Med, Houston, TX USA
[3] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX USA
[4] Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA
[5] Univ Iowa Hosp & Clin, Dept Microbiol, Iowa City, IA USA
关键词
D O I
10.1001/archinte.161.21.2538
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Definitions for susceptibility or resistance of Streptococcus pneumoniae to penicillin were not developed until penicillin-resistant pneumococci appeared in South Africa in the late 1970s. The definition that was accepted (which still remains in use) and later definitions of resistance to most other beta -lactam antibiotics were derived from laboratory and clinical data relating to the treatment of meningitis, not otitis media, sinusitis, or pneumonia. An understanding of the origin of these definitions helps to resolve the apparent paradox that infections of the respiratory tract due to seemingly beta -lactam-resistant pneumococci may still respond well to standard doses of these drugs. A recently sanctioned change in the definition of susceptibility to amoxicillin is helpful in eliminating the paradox for this drug, but it may create further confusion by implying that, on a microgram basis, amoxicillin is substantially more effective than penicillin or third-generation cephalosporins. This article examines definitions of susceptibility and resistance of pneumococci, highlighting areas that have led to confusion and proposing a new way of understanding them.
引用
收藏
页码:2538 / 2544
页数:7
相关论文
共 42 条
[1]   ANTIMICROBIAL RESISTANCE IN STREPTOCOCCUS-PNEUMONIAE - AN OVERVIEW [J].
APPELBAUM, PC .
CLINICAL INFECTIOUS DISEASES, 1992, 15 (01) :77-83
[2]  
Balgos AA, 1999, INT J CLIN PRACT, V53, P325
[3]   COMPARABLY MASSIVE PENICILLIN-G THERAPY IN RENAL-FAILURE [J].
BRYAN, CS ;
STONE, WJ .
ANNALS OF INTERNAL MEDICINE, 1975, 82 (02) :189-195
[4]   CEFOTAXIME BREAKPOINT FOR STREPTOCOCCUS-PNEUMONIAE [J].
CANTON, E .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (03) :616-616
[5]   Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada [J].
Chen, DK ;
McGeer, A ;
de Azavedo, JC ;
Low, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (04) :233-239
[6]  
CHERUBIN CE, 1989, REV INFECT DIS, V11, P526
[7]   Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10
[8]   Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media [J].
Dagan, R ;
Johnson, CE ;
McLinn, S ;
Abughali, N ;
Feris, J ;
Leibovitz, E ;
Burch, DJ ;
Jacobs, MR .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (02) :95-104
[9]  
DAGAN R, 1997, 37 INT C ANT AG CHEM, P346
[10]   PHARMACOKINETICS AND CEREBROSPINAL-FLUID BACTERICIDAL ACTIVITY OF CEFTRIAXONE IN THE TREATMENT OF PEDIATRIC-PATIENTS WITH BACTERIAL-MENINGITIS [J].
DELRIO, M ;
MCCRACKEN, GH ;
NELSON, JD ;
CHRANE, D ;
SHELTON, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1982, 22 (04) :622-627